- Home
- LGND
as 12-17-2024 4:00pm EST
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
| Founded: | 1987 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 2.3B | IPO Year: | 1992 |
| Target Price: | $145.00 | AVG Volume (30 days): | 107.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 2.47 | EPS Growth: | 160.46 |
| 52 Week Low/High: | $67.53 - $129.90 | Next Earning Date: | 11-07-2024 |
| Revenue: | $152,422,000 | Revenue Growth: | -0.76% |
| Revenue Growth (this year): | 26.86% | Revenue Growth (next year): | 13.16% |
Latest Ligand Pharmaceuticals Incorporated News
LGND Breaking Stock News: Dive into LGND Ticker-Specific Updates for Smart Investing
Zacks Small Cap Research
2 days ago
LGND: 2025 View Calls for 17% Topline Growth
TipRanks
6 days ago
Ligand price target raised to $151 from $135 at Oppenheimer
MT Newswires
7 days ago
Oppenheimer Adjusts Ligand Pharmaceuticals Price Target to $151 From $135, Maintains Outperform Rating
MT Newswires
7 days ago
RBC Raises Price Target on Ligand Pharmaceuticals to $143 From $141, Keeps Outperform Rating
Argus Research
7 days ago
LGND: Lowering target price to $125.00
MT Newswires
8 days ago
Ligand Pharmaceuticals Issues 2025 Guidance; 2024 Forecast Reaffirmed
Business Wire
8 days ago
Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 Guidance
Argus Research
14 days ago
LGND: Lowering target price to $126.00
Compare LGND vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LGND Ligand Pharmaceuticals Incorporated - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.